ClinicalTrials.gg
Not yet recruitingNCT07720193Updated Oct 19, 2026

A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

A Phase 3 interventional study of LBL-024 for Injection and Etoposide injection in Advanced Extrapulmonary Neuroendocrine Carcinoma, sponsored by Nanjing Leads Biolabs Co.,Ltd. Not yet recruiting at 36 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Nanjing Leads Biolabs Co.,Ltd · Phase 3, Interventional, and Treatment

Updated Oct 19, 2026Start date moved8 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 39 studies in Carcinoma, Neuroendocrine with a site in China — 26 open to participants now, 27 under way, 4 of them phase 3. Carcinoma, Neuroendocrine · China.

Planned enrollment
9th of 32
280 · median 80
Started
2026
with 10 others
Phase 3
4 of 39
4 open now
Primary completion
2030-12
later than 24 of 26 live
Registered
35th of 39
by date
Lead sponsor
2 of 39
Nanjing Leads Biolabs Co.,Ltd

Among the 39 studies in Carcinoma, Neuroendocrine with a site in China, this one is the 9th largest by planned enrollment of the 32 interventional ones that give a count, is one of 11 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 24 of the 26 other live ones, and was the 35th registered.

Carcinoma, Neuroendocrine

172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 66 are open to participants now.

Browse Carcinoma, Neuroendocrine studies →

Open to participants now

26 of the 39 studies in Carcinoma, Neuroendocrine with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 47 Carcinoma, Neuroendocrine studies recruiting now, 30 (64%) set no upper age limit and 10 (21%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Carcinoma, Neuroendocrine with a site in China, or all of them as a file.
02

Study summary

This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of advanced EP-NEC patients.

Read the detailed description

A total of 280 patients with advanced EP-NEC without systemic treatment will be enrolled in this study. Eligible patients will be randomly assigned to the experimental group or control group at a ratio of 1:1.

03

Conditions studied

  • Advanced Extrapulmonary Neuroendocrine Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Agrees to follow the treatment protocol, visit schedule and laboratory test, comply with other requirements of the protocol, voluntarily enroll, and sign a written .
  2. Age ≥ 18 years (inclusive) at the time of signing informed consent.
  3. The 's physical status scoring standard (ECOG) is 0\~1.
  4. expected survival time of at least 12 weeks.
  5. According to 1.1, participants were required to have at least one .
  6. Male of and Females of childbearing age are willing to take highly effective measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with Mixed neuroendocrine-non endocrine neoplasm (MiNENs).
  2. Major surgery (other than aspiration ) within 28 days prior to the first dose of study drug or significant trauma,or required to undergo scheduled surgery during the trial.
  3. Use of immunomodulatory drugs within 14 days before the first use of study drug,Including but not limited to thymopeptide, interleukins, interferon, etc.
  4. Patients with active infection requiring intravenous anti-infective therapy within 2 weeks prior to the first dose of study drug.
  5. serious cardiac and cerebrovascular disorder.
  6. History of immunodeficiency including antibody test positive.
  7. patients with active or C.
  8. Women during pregnancy or lactation.
  9. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    LBL-024 + Etoposide + Cisplatin/carboplatin

    LBL-024 + Etoposide + Cisplatin/carboplatin. Intravenous infusion.

    Drug: LBL-024 for Injection · Drug: Etoposide injection · Drug: Cisplatin injection · Drug: Carboplatin injection

  • Active comparator
    LBL-024 placebo+ Etoposide + Cisplatin/carboplatin

    LBL-024 placebo+ Etoposide + Cisplatin/carbopla. Intravenous infusion.

    Drug: Etoposide injection · Drug: Cisplatin injection · Drug: Carboplatin injection · Drug: LBL-024 placebo for injection

Interventions

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Time from randomization to death for any reason in a clinical trial.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

Secondary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate (complete response (CR) + partial response (PR)), as assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1), refers to the percentage of study subjects who achieve a complete response or partial response.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  2. Disease Control Rate(DCR)

    Percentage of participants achieving complete response (CR) or partial response (PR) and stable disease (SD) after treatment.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  3. Duration of Response(DOR)

    DoR (per RECIST 1.1) is defined as the time from the date for first documented response of complete response (CR) or partial response (PR) to the date of first documented of disease progression or death, whichever occurs first.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  4. Progression-free Survival(PFS)

    According to the evaluation criteria of RECIST V1.1 (solid tumour),Time from first dose to disease progression or death from any cause.It was used to evaluate Time of disease no-progression or Drug resistance .

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  5. Occurrence of adverse event (AE) and serious adverse event (SAE)

    Adverse event (AE) will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0.The safety profile of combination therapy will be assessed by monitoring the adverse event (AE) and serious adverse event (SAE).

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)

  6. Cmax

    Maximum drug concentration in plasma after administration.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  7. Tmax

    After administration,Time to reach maximum drug concentration in plasma.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  8. Immunogenicity

    The immunogenicity is evaluated by the incidence of anti-drug antibodies (ADA) and neutralizing antibodies (if applicable) in subjects.Immunogenicity refers to the performance that can elicit an immune response.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

07

Study locations

36 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Dec 2030, 49 months later.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 22, 2026
StartEst.
Nov 16, 2026was Aug 2026
Primary completionEst.
Dec 22, 2030
CompletionEst.
Dec 22, 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added
Show 8 added (8 China)
  • The First Affiliated Hospital of Bengbu Medical University · Bengbu, China
  • Chongqing University Cancer Hospital · Chongqing, China
  • The First Affiliated Hospital of Fujian Medical University · Fuzhou, China
  • The First Affiliated Hospital of Xiamen University · Xiamen, China
  • AnYang Tumor Hospital · Anyang, China
  • The First Affiliated Hospital of Henan Medical University · Xinxiang, China
  • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, China
  • Liaoning Cancer Hospital and Institute · Shengyang, China
Oct 19, 2026
Start date
Aug 22, 2026→Nov 16, 2026
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    8 sites added
    Show 8 added (8 China)
    • The First Affiliated Hospital of Bengbu Medical University · Bengbu, China
    • Chongqing University Cancer Hospital · Chongqing, China
    • The First Affiliated Hospital of Fujian Medical University · Fuzhou, China
    • The First Affiliated Hospital of Xiamen University · Xiamen, China
    • AnYang Tumor Hospital · Anyang, China
    • The First Affiliated Hospital of Henan Medical University · Xinxiang, China
    • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, China
    • Liaoning Cancer Hospital and Institute · Shengyang, China
    Start date Aug 22, 2026→Nov 16, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07720193
Lead sponsor
Nanjing Leads Biolabs Co.,Ltd
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Dec 22, 2030 (estimated)
Completion
Dec 22, 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Lin Shen
Contact
doctorshenlin@sina.cn
010-88121122
Lin Shen
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-L1/4-1BB Bispecific Antibody LBL-024

Start the discussion